Cheng Xu

Dr. Cheng Xu


Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 April 2021 in Cancer Research and Treatment
Verified
Journal Article
Open access
PDF file
STSi-Qi Tang
Si-Qi Tang
LTLing-Long Tang
Ling-Long Tang
YMYan-Ping Mao
Yan-Ping Mao
WLWen-Fei Li
Wen-Fei Li
LCLei Chen
Lei Chen
JMJun Ma
Jun Ma
Purpose The occurrence pattern of immune-related adverse events (irAEs) induced by immune checkpoint inhibitor (ICI) in cancer treatment remains unclear. Materials and Methods Phase II-III clinical trials that evaluated ICI-based treatments in cancer and were published between January 2007 and December 2019 were retrieved from public electronic databases. The pooled median time to onset (PMT-O), resolution (PMT-R), and immune-modulation resolution (PMT-IMR) of irAEs were generated using the metamedian package of R software.Results Twenty-two eligible studies involving 23 clinical trials and 8,436 patients were included. The PMT-O of all-grade irAEs ranged from 2.2 to 14.8 weeks, with the longest in renal events. The PMT-O of grade ≥ 3 irAEs was significantly longer than that of all-grade irAEs induced by programmed cell death protein 1 (PD-1) and its ligand 1 (PD-L1) inhibitors (27.5 weeks vs. 8.4 weeks, p < 0.001) and treatment of nivolumab (NIV) plus ipilimumab (IPI) (7.9 weeks vs. 6.0 weeks, p < 0.001). The PMT-R of all-grade irAEs ranged from 0.1 to 54.3 weeks, with the shortest and longest in hypersensitivity/infusion reaction and endocrine events, respectively. The PMT-IMR of grade ≥ 3 irAEs was significantly shorter than that of all-grade irAEs caused by PD-1/PD-L1 blockade (6.9 weeks vs. 40.6 weeks, p=0.002) and NIV+IPI treatment (3.1 weeks vs. 5.9 weeks, p=0.031).Conclusion This study revealed the general and specific occurrence pattern of ICI-induced irAEs in pan-cancers, which was deemed to aid the comprehensive understanding, timely detection, and effective management of ICI-induced irAEs.

1 August 2022 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
YZYuan Zhang
Yuan Zhang
LCLei Chen
Lei Chen
GHGuo-Qing Hu
Guo-Qing Hu
NZNing Zhang
Ning Zhang
XZXiao-Dong Zhu
Xiao-Dong Zhu
LTLing-Long Tang
Ling-Long Tang
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically on the based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. Clinical Trial Updates provide an opportunity to disseminate additional results from studies, published in JCO or elsewhere, for which the primary end point has already been reported. We previously reported significantly improved failure-free survival using gemcitabine plus cisplatin induction chemotherapy in locoregionally advanced nasopharyngeal carcinoma. Here, we present the final overall survival (OS) analysis. In this multicenter, randomized trial, patients were assigned to be treated with concurrent chemoradiotherapy alone (standard therapy, n = 238) or gemcitabine and cisplatin induction chemotherapy before concurrent chemoradiotherapy (n = 242). With a median follow-up of 69.8 months, the induction chemotherapy group had a significantly higher 5-year OS (87.9% v 78.8%, hazard ratio, 0.51 [95% CI 0.34 to 0.78]; P = .001) and a comparable risk of late toxicities (≥ grade 3, 11.3% v 11.4%). Notably, the depth of the tumor response to induction chemotherapy correlated significantly and positively with survival (complete response v partial response v stable/progressive disease, 5-year OS, 100% v 88.4% v 61.5%, P = .005). Besides, patients with a low pretreatment cell-free Epstein-Barr virus DNA load (< 4,000 copies/mL) might not benefit from induction chemotherapy (5-year OS, 90.6% v 91.4%, P = .77). In conclusion, induction chemotherapy before concurrent chemoradiotherapy improved OS significantly in patients with locally advanced nasopharyngeal carcinoma, without increasing the risk of late toxicities. Tumor response to induction chemotherapy and pretreatment cell-free Epstein-Barr virus DNA might be useful to guide individualized treatment.

3 May 2021 in JAMA Network Open
Verified
Journal Article
Open access
PDF file
ZCZi-Hang Chen
Zi-Hang Chen
KYKai-Bin Yang
Kai-Bin Yang
YZYuan-Zhe Zhang
Yuan-Zhe Zhang
CWChen-Fei Wu
Chen-Fei Wu
DWDan-Wan Wen
Dan-Wan Wen
LLLi Lin
Li Lin
Cancer has the largest disease burden worldwide and is the second leading cause of death globally1 and in the United States.2 Unmarried patients with cancer (including those who have never married, are separated, divorced, widowed, or in a domestic partnership) are at a higher risk of dying from cancer than married patients.3-7 In the United States, the proportion of unmarried people is increasing; in 2020, 50% of US residents were married, and this percentage has decreased 9 percentage points during the past 25 years.8 In recent decades, the US marriage rate has decreased, from a rate of 9.8 marriages per 1000 people in 1990 to a rate of 6.5 per 1000 people in 2018, reaching a historic low.9 As unmarried patients with cancer have poorer cancer-specific survival (CSS) and their proportion is steadily increasing, details of the mechanisms underlying the association between marital status and CSS should be explored, as they may inform specific interventions for unmarried patients that will improve their CSS.

19 February 2025 in CA: A Cancer Journal for Clinicians
Verified
Journal Article
Open access
LTLing-Long Tang
Ling-Long Tang
LCLin Chen
Lin Chen
GXGui‐Qiong Xu
Gui‐Qiong Xu
NZNing Zhang
Ning Zhang
CHCheng‐Long Huang
Cheng‐Long Huang
JMJun Ma
Jun Ma
Background: Nearly 90% locoregionally advanced nasopharyngeal carcinoma (LANPC) responds to induction chemotherapy (IC) with significant tumor volume shrinkage. Radiotherapy always follows IC, and reduced volume has been proposed. However, the efficacy and safety of reduced‐volume radiotherapy is uncertain. Methods: In this multi‐center, noninferiority, randomized, controlled trial, patients with LANPC who completed IC were randomly assigned (1:1) to receive reduced‐volume radiotherapy based on post‐IC tumor volume (Post‐IC group) or conventional volume radiotherapy based on pre‐IC tumor volume (Pre‐IC group). The primary endpoint was locoregional relapse‐free survival, with a noninferiority margin of 8%. Secondary endpoints comprised adverse events, and quality of life (QoL). Results: Between August 7, 2020, and May 27, 2022, 445 patients were randomly assigned to Post‐IC ( n = 225) or Pre‐IC ( n = 220) groups. The average volume receiving radical dose was 66.6 cm 3 in Post‐IC group versus 80.9 cm 3 . After a median follow‐up of 40.4 months, the 3‐year locoregional relapse‐free survival was 91.5% in the Post‐IC group versus 91.2%, with a difference of 0.3% (95% confidence interval −4.9% to 5.5%). The incidence of grade 3‐4 radiation‐related toxicity was lower in the Post‐IC group including: acute mucositis (19.8% vs 34.1%), late otitis media (9.5% vs 20.9%) and late dry month (3.6% vs 9.5%). The Post‐IC group had better QoL for global health status, physical functioning, emotional functioning, dry mouth and sticky saliva. Conclusions: In this trial, reduced‐volume radiotherapy was noninferior to conventional volume radiotherapy in locoregional relapse‐free survival, and was associated with lower toxicities and improved QoL. (ClinicalTrials.gov identifier NCT04384627).

17 January 2019 in Radiation Oncology
Verified
Journal Article
Open access
PDF file
LPLiang Peng
Liang Peng
JLJin-Qi Liu
Jin-Qi Liu
CXCheng Xu
Cheng Xu
XHXiao-Dan Huang
Xiao-Dan Huang
LTLing-Long Tang
Ling-Long Tang
JMJun Ma
Jun Ma
Induction chemotherapy (IC) now is gaining recognition for the treatment of nasopharyngeal carcinoma (NPC). The current study was conducted to examine the association between prognosis and the interval between IC and radiotherapy (RT) in NPC patients. Patients with newly diagnosed, non-metastatic NPC who were treated with IC followed by RT from 2009 to 2012 were identified from an inpatient database. Overall survival (OS), disease-free survival (DFS), distant metastasis-free survival (DMFS) and locoregional recurrence-free survival (LRFS) were compared between those with interval ≤ 30 and > 30 days by Kaplan-Meier and log-rank analyses; Cox modeling was used for multivariable analysis. A total of 668 patients met inclusion criteria with median follow-up of 64.4 months. Patients were categorized by interval: 608 patients with interval ≤ 30 days, and 60 with interval > 30 days. The 5-year OS, DFS, DMFS and LRFS rates were 86.6, 78.2, 88.0 and 89.8% for patients with interval ≤ 30 days, respectively, and 69.2, 64.5, 71.2 and 85.1% for patients with interval > 30 days, respectively. The prolonged interval was a risk factor for OS, DFS and DMFS with adjusted hazard ratios (95% confidence intervals) were 2.44 (1.48–4.01), 1.99 (1.27–3.11) and 2.62 (1.54–4.47), respectively. Prolonged interval > 30 days was associated with a significantly higher risk of distant metastasis and death in NPC patients. Efforts should be made to avoid prolonged interval between IC and RT to minimize the risk of treatment failure.

2 December 2024 in Journal of Clinical Investigation
Verified
Journal Article
Open access
PDF file
CZChuqing Zhang
Chuqing Zhang
ZDZhenji Deng
Zhenji Deng
JWJiawei Wu
Jiawei Wu
CDCong Ding
Cong Ding
ZLZhe Li
Zhe Li
XLXiaoyu Liang
Xiaoyu Liang
Type I IFNs (IFN-Is) induced by radiotherapy (RT) are critical for its efficacy, while the mechanism by which tumor cells inhibit IFN-I production remains largely unsolved. By an unbiased CRISPR screen, we identified hemeoxygenase 1 (HO-1) as an RT-related regulator of IFN-I production. Mechanistically, the ER-anchored, full-length HO-1 disrupted stimulator of IFN genes (STING) polymerization and subsequent coat protein complex II–mediated (COPII-mediated) ER-Golgi transportation, leading to hampered activation of downstream signaling. This process was exacerbated by the upregulation of HO-1 expression under RT. Importantly, RT also induced HO-1 cleavage. Cleaved HO-1 underwent nuclear translocation, interacted with cyclic GMP-AMP synthase (cGAS), and inhibited its nuclear export upon irradiation, leading to suppressed 2′3′-cyclic GMP-AMP (cGAMP) production. Furthermore, we revealed that HO-1 inhibitors could enhance local and distant tumor control of RT in vivo. Clinically, higher HO-1 expression was associated with a poorer prognosis and earlier tumor relapse after RT in multiple types of patient tumors. Collectively, through comprehensive inhibition of the cGAS/STING pathway, HO-1 strongly inhibited RT-induced IFN-I production, and targeting HO-1 was shown to be a promising RT-sensitizing therapeutic strategy.